Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico

Multiple Indications Cancer Clinical Trial

Official title: Postmarketing Study to Assess the Safety of Nivolumab as a First- and Second-line Treatment in Patients With Metastatic Melanoma or as a Second-line Treatment for Metastatic Lung Cancer (Squamous and Nonsquamous), Metastatic Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adult Patients in Mexico

Status Withdrawn

Clinical Trial Summary

This is a post-marketing study of patients who started nivolumab as first- or second-line therapy for metastatic melanoma or as second-line therapy for metastatic squamous non-small cell lung cancer (SqNSCLC) , metastatic non-SqNSCLC, metastatic renal cell carcimona (RCC), or recurrent or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN), or third-line therapy for classical Hodgkin lymphoma (cHL) in Mexico.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma, Squamous Cell
• Hodgkin Disease
• Kidney Neoplasms
• Multiple Indications Cancer
• Neoplasms, Squamous Cell
• Squamous Cell Carcinoma of Head and Neck

• NCT number: NCT03161613
• Study type: Observational
• Source: Bristol-Myers Squibb
• Status: Withdrawn
• Start date: July 17, 2017
• Completion date: April 1, 2019